SCARP-DIAL (SGLT2i for CARdiovascular Protection in DIALysis)

Condition studied

Chronic dialysis, Cardiovascular disease

Investigational medicinal product(s)

Eligibility

Primary endpoint

Time to first major adverse cardiovascular event (MACE) consisting of a composite of cardiovascular death, hospitalization or urgent visit for HF, myocardial infarction and ischemic stroke.

Endpoint detail

Total number of major cardiovascular events (MACE) consisting of a composite of cardiovascular death, hospitalization or urgent visit for HF, myocardial infarction and ischemic stroke, Time to first cardiovascular death or hospitalization or urgent visit for HF, Time to first all-cause hospitalization, Time to first hospitalization or urgent visit for HF, Time to cardiovascular death, Time to all-cause mortality, Change in symptom score according to Kansas City Cardiomyopathy Questionnaire (KCCQ-12), Change in recovery time after hemodialysis sessions (patient-reported), Time to first non-fatal myocardial infarction, Time to first non-fatal ischemic stroke, Time to first cardiac revascularizations, Time to first new onset atrial fibrillation/flutter